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Abstract 
Background: Definitive cisplatin-based is increasingly delivered as the treatment of choice for patients 
with head and neck cancer. Sensorineural hearing loss is a significant long term side effect of cisplatin-
based chemoradiation and is associated with potential major quality of life issues for patients. 
Purpose: The purpose of this manuscript was to review the mechanism behind sensorineural hearing 
loss in patients treated with cisplatin-based chemoradiation, including incidence, the contributions of 
radiotherapy and cisplatin to sensorineural hearing loss and the impact of the toxicity on patient quality 
of life. 
Methods: Database searches were conducted through PubMed (National Centre for Biotechnology 
Information) and OvidSP Medline via the Queensland University of Technology Library website. 
General article searches were conducted through the online search engine Google Scholar. Articles 
were excluded if the full-text was unavailable, they were not in English or if they were published prior to 
1990. Keywords included hearing loss, ototoxicity, cancer, quality of life, cisplatin and radiotherapy. 
Results/Discussion: The total number of journal articles accessed was 290. Due to exclusion criteria, 
129 articles were deemed appropriated for review. Findings indicated that sensorineural hearing loss is 
a significant, long term complication for patients treated with cisplatin-based chemoradiation. Current 
literature recognises the ototoxic effects of cisplatin and cranial irradiation as separate entities, however 
the impact of combined modality therapy on sensorineural hearing loss is seldom reported. Multiple risk 
factors for hearing loss are described, however there are contradictory opinions on incidence and 
severity and the exact radiation dose threshold responsible for inducing hearing loss in patients 
receiving combined modality therapy. Sensorineural hearing loss creates a subset of complexities for 
patients with head and neck cancer and that these patients face significant quality of life impairment. 
Conclusion: The literature review identified that sensorineural hearing loss is a major quality of life 
issue for patients treated with cisplatin-based chemoradiation for head and neck cancer. Further 
investigation evaluating the contribution of cisplatin-based chemoradiation to sensorineural hearing loss 
and the subsequent effect on patient quality of life is warranted. 
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Introduction 
Sensorineural hearing loss (SNHL) is a major complication of treatment for patients with head and neck 
cancer (HNC) treated with cisplatin-based chemoradiation (CbCRT). CbCRT is increasingly used in the 
management of HNC, with positive impact on overall survival (OS) [1]. However, both cisplatin and 
radiation are known to be ototoxic and as such, the rate of treatment-induced SNHL is significantly 
higher with combined modality therapy.  
 
SNHL is a type of hearing loss incurred by damage to the cochlea or retro-cochlea region or from 
damage to the cranial nerve VIII and central auditory pathways. The mechanism underlying SNHL, 
following CbCRT, remains undefined. There is evidence to suggest it is related to a radiation-induced, 
pathophysiologic change in the auditory system, beginning at the Eustachian tube and extending to the 
brainstem [2]. Aetiologies of SNHL may include vascular insufficiency, reduced number of capillaries, 
degeneration of endotheliocytes in vessels, loss of cells in the Organ of Corti and degeneration of the 
stria vascularis, and atrophy of the spiral ganglion cells and the cochlea nerve [3-5]. 
 
Advances in treatment techniques over the past decade have substantially improved the prognosis for  
patients with HNC, with 5-year locoregional control (LRC) greater than 80 % in patients with locally 
advanced disease [5]. As such, it is important to consider the impact of treatment on quality of life 
(QOL), as these patients are living longer with the side effects of their treatment. The aim of this 
manuscript was to review the mechanism behind SNHL, in patients treated with CbCRT, including 
incidence, the contributions of radiotherapy and cisplatin to SNHL and the impact of the toxicity on 
patient QOL. 
 
Methods 
The literature was reviewed for relevant studies exploring HNC treatment modalities, particularly 
CbCRT and specific health outcomes including SNHL. The electronic databases OvidSP MEDLINE and 
PubMed (National Centre for Biotechnology Information) were searched via the Queensland University 
of Technology Library website. A combination of the following keywords were used: hearing loss, 
ototoxicity, quality of life, cancer, cisplatin and radiotherapy. The Google Scholar database was also 
searched using identical keyword combinations. In addition, citation and related searches were 
completed using author names, reference checks and the PubMed “related citations’ function. All 
relevant retrospective and prospective cohort studies, cross-sectional and case-control studies, 
published in peer reviewed journals, between 1990 and 2013 were reviewed by one author. Only articles 
that were published in English with available full-text were included.  
 
The searches identified 290 articles, of which 129 met the inclusion criteria. A further 53 articles were 
excluded as they reported on a combination of chemotherapeutic drugs, alternate chemotherapy 
infusion methods, diagnoses other than head and neck or paediatric cohorts, leaving 76 articles suitable 
for review.   
  
Results & Discussion 
Clinical Context 
Over the past few decades, the incidence of patients presenting with HNC has been on a steady incline 
[6-9]. This rising incidence does not correlate with the conventional HNC risk factors of excessive 
tobacco and alcohol exposure but rather, it aligns with emerging epidemiologic data that confirms the 
increasing presence of virally-mediated HNC [10,11]. The recognition of virally-mediated tumours has 
impacted the demographic of patients diagnosed with HNC¸ with the disease predominantly affecting 
middle-aged, white males with higher socioeconomic status and with no, or relatively low, smoking 
history [7-9].  
 
Current treatment paradigms have also evolved. The need to optimise tumour control whilst preserving 
organ function is integral and as such, definitive radiotherapy combined with chemotherapy is the 
current standard of care when functional preservation is desired. Multiple studies have reported 
improved progression free survival (PFS) and OS rates in patients receiving concurrent chemoradiation 
(CCRT) when compared to those receiving radiation alone [12,13]. Chan et al (2002) [13] randomized 
358 patients with nasopharyngeal carcinoma to receive CCRT or radiation alone and concluded that 2 
year PFS strongly favoured the CCRT arm (76% vs. 69%). Most recently, a meta-analysis of 
chemotherapy for HNC (MACH-NC) [14] extracted data from 87 trials, from 16485 patients diagnosed 
with carcinoma of the oral cavity, oropharynx, hypopharynx and larynx. The patients were randomly 
assigned to receive definitive radiation therapy alone or definitive chemoradiation. The authors 
concluded that CCRT yielded an improvement in OS, with a 6.5% absolute decrease in mortality at 5 
years.  
 
Furthermore, multiple studies reported that PFS and LRC are improved when cisplatin is integrated as 
the chemotherapeutic agent in CCRT. The Radiation Therapy Oncology Group (RTOG) 91-11 [15] trial 
found that concurrent cisplatin and radiotherapy yielded a significantly (P = 0.006) higher 5 year disease 
free survival (36%) than radiotherapy alone (27%) in patients with laryngeal carcinoma. The authors 
further reported that the rate of LRC was also significantly (P = 0.03) better with radiotherapy and 
concurrent cisplatin (78% vs. 61% with induction cisplatin plus fluorouracil followed by radiotherapy and 
56% with radiotherapy alone). 
 
Nevertheless, whilst the prognosis for this disease has substantially improved over the past two 
decades, the QOL of this cohort of patients remains suboptimal due to treatment related toxicities [8,10]. 
Cisplatin is associated with numerous toxicities that limit the intensity of individual therapeutic regimen 
[16]. Cooper et al (2004) [17] reported that the addition of high dose cisplatin to radiotherapy induces 
an increase in the incidence of acute adverse effects from 34 % to 77 %, thus resulting in numerous 
functional side effects and creating a prolonged need for supporting medical and allied health services, 
These side effects can include the acute toxicities of dysphagia and mucositis; or long term effects such 
as xerostomia. SNHL is another recognised, long term, treatment related side effect that has become 
a prominent issue, particularly in this younger cohort.  
 Considering the toxicities associated with CbCRT, a number of trials are revising radiotherapy regimen 
and investigating the effects of de-escalating treatment for some of these patients [18,19]. Irrespective, 
a large proportion of these patients will continue to receive CbCRT for their HNC treatment. 
 
SNHL 
Given the ototoxic properties of cisplatin and radiation as separate entities, it is unsurprising that SNHL 
is a major toxicity of combined modality therapy. SNHL can present as unilateral or bilateral hearing 
loss and can be permanent; where there is irreversible hearing loss, or transient; where partial hearing 
ability will be recovered [20]. Either high frequency hearing; relating to speech perception in a noisy 
background, or low frequency hearing; the relation of speech perception in a quiet room, can be 
affected. 
 
Sensorineural hearing function is evaluated using a pure tone audiogram. This is a subjective, 
behavioural measurement of hearing threshold, relying on patient response to pure tone stimuli. It 
utilises pure-tone air conduction thresholds, where the ear is stimulated using air and the hearing ability 
of the external auditory canal, the middle ear, and the integrity of the inner ear, eighth cranial nerve, 
and central auditory pathways are tested. A bone conduction threshold (BCT) test is also performed 
where the sensitivity of a signal transmitted through the bones of the skull to the cochlea and through 
the auditory pathways of the brain is assessed. Traditionally, SNHL is defined as a clinically significant 
increase (≥ 10 dB) in BCT at the key human speech frequencies (0.5 - 4.0 kHz), as seen in pure-tone 
audiometry [20,21].  
 
SNHL Incidence 
SNHL has been observed at levels of 33% in patients treated with radiotherapy alone and it is reported 
that there is negligible risk of hearing loss when using low dose cisplatin alone (< 360 mg/m2, 
cumulatively) [2,13].  However, the integration of cisplatin to radiotherapy treatment regimen, increases 
the risk of SNHL risk to 60 - 80% at speech frequencies [2,22]. Furthermore, Kasibhatla et al (2007) 
[23] reported that the addition of cisplatin to a radiotherapy treatment plan increases the biological 
equivalent dose by approximately 10 Gy using standard fractionation. 
 
The tendency for SNHL to increase over time was reported by both Ho et al (1999) [24] and Kwong et 
al (1996) [25] who prospectively assessed patients receiving CbCRT, using three dimensional 
conformal radiotherapy (3DCRT).  Ho et al (1999) [24] reported that 41% of patients experienced 
transient SNHL and that hearing further deteriorated in 25% of patients with persistent SNHL for up to 
two years following treatment. Similarly, Kwong et al (1996) [25] reported increased hearing loss up to 
two years following treatment but also identified a recovery period for up to five years after treatment.  
 
There are numerous factors suggested to increase the risk of developing SNHL. Age-related, post-
radiation SNHL is most often reported [20,22,24-28].  Kwong et al (1996) [25] suggested males may be 
more likely to develop the complication, reporting that rates of SNHL were 29.4 % for males and 15.5 
% for females (p = 0.0132), Other investigators reported that gender and ethnicity had limited statistical 
significance as a predictive factor for SNHL [13,22]. A number of studies supported a direct relationship 
between SNHL and pre-therapy hearing capability, with better pretreatment hearing scores relating to 
increased levels of SNHL [20,26,27]. Cranial irradiation and dose to the inner ear were both strong 
predictors for the development of SNHL but the effects of dose per fraction (< or > 2Gy) and bi-daily 
fractionation require further investigation [2,20,24-26]. 
 
SNHL and Chemotherapy 
There are numerous chemotherapy related factors that were documented as risk factors for SNHL. The 
fractional dose of cisplatin infused per cycle, as well as the cumulative dose, were reported to be the 
most important influence on the risk of developing SNHL [22,26,29,30]. When combined with 
radiotherapy, low dose cisplatin (< 40 mg/m2 per week) resulted in less ototoxicity than high dose 
cisplatin (100 mg/m2, every 3 weeks) reducing the incidence of SNHL from 78 % to 31 % [30,31]. 
Cumulative cisplatin doses in excess of 400 mg/m2 or fractional cisplatin dose greater than 150 mg/m2 
were also reported to substantially increase the degree of SNHL experienced by patients [30,32,33]. 
Furthermore, chemotherapy administration schedule was reported to be a major risk factor [22,26,30]. 
Increased levels of SNHL have been reported in patients treated with adjuvant and concurrent cisplatin, 
when compared to those receiving neoadjuvant chemotherapy followed by radiotherapy [4,20,24,25]. 
 
SNHL and Radiotherapy 
Whilst not intentionally included in radiation treatment field, the volume of inner ear irradiated is 
dependent upon the extent of clinical disease to be treated. However, the correlation between the extent 
of clinical disease to be treated using radiotherapy and the magnitude of hearing loss is unavailable in 
current literature. Additionally, diagnostic subgroups at risk of developing SNHL have been sparsely 
reported. Ondrey et al. (2004) [34] demonstrated that patients with nasopharyngeal carcinomas were 
at greatest risk for receiving high radiation doses to otologic structures as the cochlea always received 
the full prescribed dose of radiation. Hitchcock et al. (2009) [29] also reported that nasopharyngeal 
patients were at risk but further concluded that patients with disease involving the parotid, paranasal 
sinus, brain or the area covering the parapharyngeal space and pterygo-palatine fossa were at equal 
risk. Similarly, Jereczek-Fossa et al. (2003) [3] reported that up to 50 % of nasopharyngeal patients will 
develop SNHL but also concluded that patients with parotid malignancies have an increased risk, with 
up to 53 % of patients developing the complication.  
 
Whilst the mechanism underlying SNHL following radiation remains undefined, the importance of 
limiting radiation dose to the cochlea and surrounding structures is emphasized throughout the literature 
[2,13,20,21]. Oh et al (2004) [2] retrospectively analysed 32 nasopharyngeal patients who received 
CCRT and concluded that minimising radiation dose to the inner ear was essential to reduce SNHL. 
Similarly, Honore et al (2002) [27] and Herrmann et al (2006) [35] reported the incidence of SNHL could 
be correlated with increasing radiation dose to the cochlea, with a reduction in the hearing threshold of 
0.3 and 0.2 dB per Gy, respectively. 
 
In a retrospective review of 325 patients who received CbCRT, Bhandare et al (2007) [36] reported that 
there was a 37 % chance of developing clinically overt SNHL in patients who received doses of above 
60.5 Gy to the cochlea, compared to 3 % at doses below this. In previous studies, the threshold 
maximum radiation dose for clinically significant hearing loss was reported as 10 Gy, 30-65 Gy, 48 Gy 
and 50 Gy [24,29,30,37]. Bentzen et al (2010) [38] described the Quantitative Analyses of Normal 
Tissue Effects Criteria (QUANTEC) and reported the normal tissue complication probability for the 
cochlea. The authors reported that dose-volume modelling indicates that for conventional therapy the 
dose to the cochlea should be limited to ≤ 45 Gy and ≤ 35 Gy if more conservative approach was 
required.  SNHL incidence and recommended cochlea tolerances are described in Table 1. 
 
The increasing utilisation of intensity-modulated radiotherapy (IMRT) for HNC has allowed for better 
dose conformation and facilitated cochlea sparing without the compromise of tumour coverage [5,39]. 
The inner ear does receive a clinically measureable dose from the primary beam entry and exit points 
and scatter radiation, however organ at risk constraints, resulting from IMRT, minimise this dose. 
Wolden et al. (2006) [39] reported that IMRT achieved a 4 % reduction in the magnitude of SNHL in 
patients with nasopharyngeal carcinoma, when compared to 3D CRT. Oh et al (2004) [2] reviewed 
IMRT treatment techniques and substantially reduced the maximum radiation dose to the inner ear from 
69.6 ± 11.8 Gy with 3D CRT to 63.4 ± 9.1Gy with IMRT. The authors further reported that a 6.2 Gy 
reduction resulted in a decrease in the incidence of SNHL, from 68.2 % (15 of 22) to 0 % (0 of 8). 
Additional research, conducted in paediatric cohorts, further suggests that treatment with IMRT can 
achieve a 51 % reduction in SNHL incidence [40,41]. 
 
SNHL and Patient QOL 
SNHL is one of the few chronic conditions for which, in most cases, there are no effective medical or 
surgical treatments [42]. Where appropriate, audiologic intervention may involve amplification through 
the use of hearing aids [43]. Nonetheless, SNHL creates a subset of complexities for patients with HNC, 
in addition to any difficulties they may already experience with swallowing and speech, or any 
psychological effects caused by loss of function or change in body image. 
 
A decline in hearing, at any frequency, significantly affects the long term QOL of a patient due to a 
reduction in the perception of acoustic information for accurate speech analyses [29,44]. Consequently, 
adverse effects on physical, cognitive, emotional, behavioural and social function have been reported 
[45]. Slawinski et al (1993) [46] suggested that hearing impairment alters a person’s ability to 
communicate with others and seriously affects interpersonal relationships. Carabellese et al (1993) [47] 
reported increased risk for depression and decreased self-sufficiency in activities of daily living in 
patients with SNHL. Other studies report that hearing loss is associated with compromise of cognitive 
function, learning ability and communication resulting in isolation and depression, loneliness, altered 
self-esteem and diminished functional status [29,44,45,48,49]. 
 
SNHL Challenges 
For this review, authors note a lack of consistency in the reporting of SNHL, with variation in: (1) the 
shift in hearing threshold that is defined as clinically significant (eg 30 dB [13], 20 dB [1,26], 15 dB 
[2,25], 10 dB [26]); and (2) time to follow up (eg., 24 months [13], 12 months [1], 12 weeks [9,30], 31 
days [31]). Some series use two-dimensional or three-dimensional treatment planning without accurate 
dose data for the hearing apparatus and the dose-fractionation schemes vary from the current standard 
of care [1,2,26,27]. Furthermore, small sample sizes (< 50), differing or non-existent chemotherapy 
regimen, as well as reported difficulties in accurately defining inner ear structures, meant that 
determination of the impact of treatment protocols on SNHL was complicated.  
 
Conclusion 
In summary, advances in treatment techniques have greatly improved the prognosis for patients with 
HNC, however patient QOL remains suboptimal due to treatment related toxicities. Despite substantive 
variation in published studies, it is evident that CbCRT increases the ototoxic effects of cisplatin and 
radiotherapy and significantly reduces the radiation toxicity threshold of the auditory and vestibular 
structures. SNHL greatly diminishes the QOL for patients with HNC, who otherwise have a relatively 
good prognosis. In order to address this, further investigation is imperative to determine; (a) those 
patients who are at risk of SNHL and (b) whether treatment can be successfully modified to reduce this 
risk.  
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RT = both 3DCRT and IMRT used, HDC = Concurrent High Dose Cisplatin, LDC = Concurrent Low Dose Cisplatin 
*Study reported SNHL incidence in reference to the percentage of patients assessed 
^ Study reported SNHL incidence in reference to the percentage of ears assessed 
   Table 1. Sensorineural hearing loss incidence and cochlea dose in head and neck cancer 
Study  Sample 
Size 
Mean 
Cochlea 
Dose (Gy) 
Median 
Follow Up 
(months) 
CbCRT Regimen Median 
RT Dose 
(Gy) 
SNHL Criteria SNHL 
Incidence 
Recommended  
cochlea 
threshold (Gy) 
Chen et al., 2006 
[1] 
22 48.5 29 
RT + HDC vs RT + 
neoadjuvant HDC/5-FU + HDC 
70 
> 20 dB at one Hz 
> 10 dB at two Hz 
57 %^ < 48 
Oh et al., 2004 [2] 32 66.6 40  
RT + neoadjuvant LDC/5-FU + 
LDC 
70 > 15 dB at 4 kHz + PTA 60.1%^ < 65. 0 
Petsuksiri et al., 
2011 [5] 
27 51 14 
IMRT + neoadjuvant HDC/5-
FU + HDC vs 3DCRT + 
neoadjuvant HDC/5-FU + HDC 
68 > 15 dB at 4 kHz + PTA 44 %* < 50 
Chan et al., 2009 
[13] 
87 48.9 24  
RT vs RT + HDC vs RT + 
noncurrent HDC 
70 
 
> 15 dB at 4 kHz 56.4%* < 47 
Pearson et al., 2006 
[16] 
37 34.0 1 3DCRT + HDC 70 > 10 dB at 4 kHz + PTA 34.5 %* < 40 
Ho et al., 1999 [24] 294 81 30  
3DCRT vs 3DCRT + HDC + 
epirubicin 
59.5 > 10 dB at 4 kHz + PTA 31.1 %^ N/A 
Pan et al., 2005 [26] 35 47.4 6  3DCRT vs 3DCRT + HDC 64 ≥ 10 dB at any Hz 45.7 %* < 45 
Hitchcock et al., 
2008 [29] 
62 10.56 2 
RT vs RT + LDC vs RT + 
HDC 
66 ≥ 10 dB at any Hz 41.1 %^ < 10 
Zuur et al., 2009 
[30] 
101 11.4 3  IMRT 63 
≥ 15 dB shift at 2+ 
contiguous Hz 
13 %^ < 48 
Bhandare et al., 
2007 [36] 
42 66.5 65 
3DCRT + HDC (neoadjuvant, 
concurrent or adjuvant) 
N/A 
≥ 15 dB shift at 2+ 
contiguous Hz 
26.1 %* < 60 
Wolden et al., 2006 
[39] 
74 55.6 35  IMRT vs IMRT + HDC 70 
≥ 15 dB shift at 2+ 
contiguous Hz 
47 %* 
Investigation 
pending 
